PositoAI/ US/ Climb Bio, Inc.

Climb Bio, Inc.

NasdaqGM: CLYM · Healthcare

Positivity Index

#4,152 / 6,774

Global

#2,003 / 4,000

United States

Positivity Score

19,850

Rank→

Overview Go Deep Penta Pattern Funda News For this company Histo

PosiRed: no active red flags

Climb Bio, Inc. — Overview & Financial Snapshot

Climb Bio, Inc. (NasdaqGM: CLYM) is a Healthcare company, ranked #4,152 of 6,774 companies globally and #2,003 of 4,000 in United States on PositoAI, with a Positivity Score of 19,850. Its market capitalisation is ₹5,714.21 Cr ($605.38M), P/E ratio is -12.9 and P/B ratio is 2.53. It has no active red flags (PosiRed) or yellow flags (PosiYellow) on record.

For financial statements, ratio trends and score history, Go Deep →

Top-ranked Healthcare companies

#3 Dogwood Therapeutics, Inc. 27,827 #8 Impact BioMedical Inc. 26,149 #13 Onconetix, Inc. 25,902 #15 Revelation Biosciences, Inc. 25,780 #18 Vyome Holdings, Inc. 25,696

— Nothing to show —

OpenAI is reading recent news...

Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies to address unmet needs for patients living with immune-mediated diseases. The company's lead product candidate is the budoprutug, an anti-CD19 monoclonal antibody for the treatment of B-cell mediated diseases. It is also developing budoprutug which is in phase 2 clinical trials for the treatment of primary membranous nephropathy and immune thrombocytopenia; and Phase 1b clinical trial indicated for the systemic lupus erythematosus. In addition, the company is developing CLYM116, a preclinical stage anti A Proliferation-inducing Ligand (APRIL) monoclonal antibody for the treatment of immunoglobin A nephropathy (IgAN) and other B-cell mediated diseases. The company was formerly known as Eliem Therapeutics, Inc. and changed its name to Climb Bio, Inc. in October 2024. Climb Bio, Inc. was incorporated in 2018 and is headquartered in Wellesley Hills, Massachusetts.

P/B Ratio 2.53

P/E Ratio -12.9

D/E Ratio 0.01

ROE -27.10%

Owes vs Owns ? 0.03× Low $0.03 owed for every $1 it owns · balance sheet Jun 2026

Dividend Yield 0.00%

Trailing EPS ₹-77.40$-0.82

Forward EPS ₹-94.67$-1.00

Beta -0.03

Market Cap ₹5,714.21 Cr$605.38M

What these numbers mean →

What does Climb Bio, Inc. do?

What is Climb Bio, Inc.'s P/E and P/B ratio?

Climb Bio, Inc. has a P/E ratio of -12.9 and a P/B ratio of 2.53.

What is Climb Bio, Inc.'s debt-to-equity ratio?

Climb Bio, Inc. has a debt-to-equity ratio of 0.01.

How much does Climb Bio, Inc. owe compared with what it owns?

Climb Bio, Inc. owes $0.03 for every $1 it owns (balance sheet Jun 2026), which is low.

What is Climb Bio, Inc.'s Positivity rank?

Climb Bio, Inc. is ranked #4,152 of 6,774 companies globally and #2,003 of 4,000 in United States on PositoAI, with a Positivity Score of 19,850.

Does Climb Bio, Inc. have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?

No active red flags (PosiRed) or yellow flags (PosiYellow) are currently on record for Climb Bio, Inc..

Where can I read the latest news about Climb Bio, Inc.?

Recent headlines about Climb Bio, Inc. from the last 30 days, with links to the original articles, are on its News page on PositoAI.

Does Climb Bio, Inc. have a PositoAI PosiShot or QR code?

Yes. A dated PosiShot of Climb Bio, Inc.'s current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.

0 / 1000

🔒 Private — stored only in this browser, never sent to PositoAI. Clear anytime in Settings.